Phase II Trial of Methotrexate in Myasthenia Gravis (MG Study)

Gender PreferenceNone
Age Group15 - 99 years
Research Start DateAugust 31, 2012
Research End DateFebruary 28, 2013
Principal InvestigatorAndrea Swenson, MD
Description
  • Purpose: to find out if methotrexate is an effective therapy for MG and if it will allow patients with MG to use less prednisone.
  • Eligibility: patients ages 15 and older with MG who are on a stable dose of Prednisone 10 mg per day or greater.
  • Duration and Involvement: patients will take study medication (methotrexate 20 mg vs. placebo) by mouth once weekly and return to clinic once per month for approximately 14 months.
Contact Info

Jeri Sieren, RN at 319-356-8744

Keywordsspan itemProp='description'>Methotrexate ; Neurology ;